Feed SRPT
SR

Sarepta Therapeutics

SRPT · NASDAQ

$20.12 -0.24% (-$0.05)
1M +10.92%
Market Cap $2.18B
P/E Ratio -
Div. Yield -
ROE 9.96%

Bulios Fair Price

$28.34

40.8% upside

Trenutna cena

$20.12

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica SRPT trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/S 1.11x
P/B 1.43x
P/E N/A
Growth
100 /100
Growing
Rev. growth 33.06%
Book val. growth 43.63%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 58.56%
FCF margin 6.66%
Net margin 6.93%
Quality
8 /100
Poor
ROIC 5.57%
Asset turnover 0.62x
ROE 9.96%
Debt
55 /100
Moderate
Debt/Equity 0.68x
Int. coverage -1.02x
Current ratio 4.42x
Stability
19 /100
Unstable
Beta 0.21x
Profitable years 0
Rev. volatility 18.71%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o SRPT
Online

O podjetju

Sarepta Therapeutics, Inc. (SRPT) is an American biopharmaceutical company focused on research, development, and commercialization of drugs for the treatment of rare genetic diseases. The company specializes in treating muscular dystrophies caused by genetic mutations. Sarepta Therapeutics develops innovative therapies based on gene therapy and RNA technologies, which have the potential to provide new treatment options for patients with rare genetic diseases. With its successful research programs and collaboration with renowned experts in the field, the company has become a significant player in the field of muscular dystrophy treatment. Shares of Sarepta Therapeutics, Inc. (SRPT) can represent an interesting investment opportunity for those seeking exposure to the biotechnology industry with a focus on treating rare genetic diseases and innovative therapeutic approaches.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Michael E. Severino

Employees

835

Headquarters

Cambridge

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.